Nicholas P. Restifo

Restifo pioneered the use of molecularly defined T cell-based immunotherapies by developing mouse models with predictive value for human clinical trials. The Restifo group was amongst the first to identify myeloid-derived cell subsets that impair anti-tumor T cell responses.

His work on immunoablation underlies many of the current generation of cellular therapies in the clinic. Dr. Restifo’s group was the first to discover a novel subset of long-lived human T memory stem cells in humans. These fundamental discoveries are aimed at improving the treatment of adults and children with metastatic cancer.